What's Happening?
City Therapeutics, a biopharmaceutical company based in Cambridge, Massachusetts, has announced the completion of a $99.5 million Series B financing round. This funding will be used to advance the company's RNA interference (RNAi) therapeutics pipeline
and accelerate its next-generation RNAi engineering platform. The financing round saw participation from new investors Viking Global Investors and Sofinnova Investments, alongside existing investors such as ARCH Venture Partners and Fidelity Management & Research Company. The company is currently conducting a Phase 1 clinical trial of CITY-FXI, targeting Factor XI for thromboembolic diseases, and has announced positive preclinical data for CITY-RBP4, a potential RNAi therapy for Stargardt disease.
Why It's Important?
The successful Series B financing round underscores the confidence investors have in City Therapeutics' innovative approach to RNAi-based medicine. The funds will enable the company to further develop its pipeline, potentially leading to breakthroughs in treating serious diseases. This development is significant for the biotechnology sector, as it highlights the growing interest and investment in RNAi technologies, which have the potential to transform treatment paradigms. The involvement of prominent investors also suggests a strong belief in the commercial viability and scientific potential of City Therapeutics' platform.
What's Next?
City Therapeutics plans to use the new capital to move two programs to clinical stage by the end of 2026, including CITY-RBP4. The company will continue to focus on expanding its RNAi platform and exploring strategic collaborations to enhance its therapeutic offerings. The addition of new investors to the board as observers indicates ongoing strategic guidance and support for the company's growth trajectory. As the company progresses, it may attract further investment and partnerships, potentially accelerating the development and commercialization of its RNAi therapies.
